lmp7

PR-924 is a selective inhibitor of tripeptide epoxyketone immunoproteasome subunit LMP-7 (IC50: 22 nM). PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities. PR-924 covalently modifies proteasomal N-terminal threonine active sites.

KZR-504 is a selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) (IC50s: 51 nM, 4.274 μM for LMP2 and LMP7, respectively).

LMP7 LMP2-IN-1(Compound 19)作为口服有效的LMP7和LMP2免疫蛋白酶体亚基抑制剂,IC50值分别为257 nM和10 nM.本化合物能有效降低抗体生成,并减少NP-OVA免疫小鼠脾脏中生发中心B细胞和血浆细胞的数量,适用于自身免疫性疾病的相关研究.

LMP7-IN-1 may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer, is an inhibitor of immunoproteasome (LMP7).

LMP7-IN-2, 作为LMP7抑制剂，适用于相关炎症性疾病与失调的治疗。

Oprozomib (PR-047) 是一种可口服的选择性肽环氧酮类蛋白酶体抑制剂，诱导多发性骨髓瘤细胞凋亡。它对蛋白酶体 (β5) 和免疫蛋白酶体 (LMP7) 的 IC50分别为 36 和 82 nM。

LMP744 hydrochloride (NSC-706744 hydrochloride) 是一种是拓扑异构酶 1 抑制剂，显示出抗肿瘤的活性。

LMP744 is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.

ONX-0914 (PR-957) 是选择性的低分子量多肽-7(LMP7)的抑制剂，LMP7 是免疫蛋白酶体的类糜蛋白酶亚单位。它是分枝杆菌蛋白酶体的非竞争性不可逆抑制剂，Ki 值为5.2 μM。它通过 HSF-1 介导的 p-TEFb 活化激活潜伏的 HIV-1。

ML604440 是一种特异性的、有效的、细胞可渗透的蛋白酶体 β1i (LMP2) 亚基抑制剂，能够破坏 MHC I 类细胞表面表达，IL-6 分泌以及 naïve T helper 向 17 T helper 细胞的分化。它可以改善实验性结肠炎和 EAE 疾病。

ONX-0914 (PR-957) TFA 为针对免疫蛋白酶体中的LMP7（低分子量多肽-7）的选择性抑制剂，LMP7为类糜蛋白酶亚单位。该化合物通过抑制细胞因子产生，减缓实验性关节炎进展，并已证实为分枝杆菌蛋白酶体的非竞争性不可逆抑制剂（Ki=5.2 μM）。此外，ONX-0914 TFA 能通过HSF-1介导的p-TEFb活化，激活潜伏的HIV-1。

Zetomipzomib maleate (KZR-616), a novel immunoproteasome inhibitor, effectively and selectively inhibits the LMP7 subunit (hLMP7 mLMP7 IC50: 39 57 nM) and LMP2 subunit (hLMP7 mLMP7 IC50: 131 179 nM) of the immunoproteasome. This compound shows promising potential for research in various autoimmune diseases.

KZR-616, a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. KZR-616 has the potential for the research of multiple autoimmune diseases[1][2]. KZR-616 also inhibits MECL-1 subunit (IC50=623 nM) and constitutive proteasome β5 subunit (IC50=688 nM). KZR-616 maintains LMP7 and LMP2 selective inhibition in MOLT-4 cells. KZR-616 (250 nM) shows a comparable cytokine inhibition profile peripheral blood mononuclear cells (PBMC)[1].KZR-616 is an immunoproteasome-selective inhibitor identified based on the optimization of ONX-0914 and PR-924 [3]. KZR-616 (5 mg/kg; i.v.; dosing was repeated on days 6, 8, 11, and 13) shows efficacy in the anticollagen antibody induced arthritis (CAIA) model[1]. [1]. Johnson HWB, et al. Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide). J Med Chem. 2018 Dec 27;61(24):11127-11143. [2]. Muchamuel T, et al. FRI0296 Kzr-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE). Annals of the Rheumatic Diseases 2018;77:685. [3]. Xi J, et al. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019;182:111646.